Relationship between p53 and p27 expression following HER2 signaling

Breast

Volumn 16, Issue 6, 2007, Pages 597-605

  Casalini, Patrizia ^a   Iorio, Marilena V ^a   Berno, Valeria ^a   Bergamaschi, Anna ^b   Børresen Dale, Anne Lise ^b   Gasparini, Patrizia ^a   Orlandi, Rosaria ^a   Casati, Barbara ^a   Tagliabue, Elda ^a   Ménard, Sylvie ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast cancer; HER2; Heregulin; Immunohistochemistry; p53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NEU DIFFERENTIATION FACTOR; NEU DIFFERENTIATION FACTOR BETA1; PROTEIN P27; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; UPREGULATION; WILD TYPE;

EID: 36349006988     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.05.007     Document Type: Article

References (25)

1. Casalini P., Iorio M.V., Galmozzi E., and Ménard S. Role of HER receptors family in development and differentiation. J Cell Physiol 200 (2004) 343-350
2. Ménard S., Balsari A., Casalini P., Tagliabue E., Campiglio M., Bufalino R., et al. HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 8 (2002) 520-525
3. Ménard S., Casalini P., Campiglio M., Pupa S.M., and Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 61 (2004) 2965-2978
4. Hognason T., Chatterjee S., Vartanian T., Ratan R.R., Ernewein K.M., and Habib A.A. Epidermal growth factor receptor induced apoptosis: potentiation by inhibition of Ras signaling. FEBS Lett 491 (2001) 9-15
5. Lehto V.P. EGF receptor: which way to go?. FEBS Lett 491 (2001) 1-3
6. Bacus S.S., Yarden Y., Oren M., Chin D.M., Lyass L., Zelnick C.R., et al. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene 12 (1996) 2535-2547
7. Casalini P., Botta L., and Ménard S. Role of p53 in HER2-induced proliferation or apoptosis. J Biol Chem 276 (2001) 12449-12453
8. Giani C., Casalini P., Pupa S.M., De Vecchi R., Ardini E., Colnaghi M.I., et al. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene 17 (1998) 425-432
9. Galmozzi E., Casalini P., Iorio M.V., Casati B., Olgiati C., and Ménard S. HER2 signaling enhances 5′UTR-mediated translation of c-Myc mRNA. J Cell Physiol 200 (2004) 82-88
10. Ménard S., Casalini P., Tomasic G., Pilotti S., Cascinelli N., Bufalino R., et al. Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat 55 (1999) 169-177
11. Huang G.C., Hobbs S., Walton M., and Epstein R.J. Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells. Br J Cancer 86 (2002) 1104-1109
12. Lloyd R.V., Erickson L.A., Jin L., Kulig E., Qian X., Cheville J.C., et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154 (1999) 313-323
13. Chiarle R., Pagano M., and Inghirami G. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res 3 (2001) 91-94
14. Shin I., Yakes F.M., Rojo F., Shin N.Y., Bakin A.V., Baselga J., et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 8 (2002) 1145-1152
15. Liang J., Zubovitz J., Petrocelli T., Kotchetkov R., Connor M.K., Han K., et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8 (2002) 1153-1160
16. Viglietto G., Motti M.L., Bruni P., Melillo R.M., D'Alessio A., Califano D., et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8 (2002) 1136-1144
17. Spataro V.J., Litman H., Viale G., Maffini F., Masullo M., Golouh R., et al. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group. Trial V Cancer 97 (2003) 1591-1600
18. Kute T., Lack C.M., Willingham M., Bishwokama B., Williams H., Barrett K., et al. Development of herceptin resistance in breast cancer cells. Cytometry A 57 (2004) 86-93
19. Nahta R., Takahashi T., Ueno N.T., Hung M.C., and Esteva F.J. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64 (2004) 3981-3986
20. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
21. Baker S.J., Markowitz S., Fearon E.R., Willson J.K.V., and Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249 (1990) 912-915
22. Wigler M., Pellicer A., Silverstein S., and Axel R. Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor. Cell 14 (1978) 725-731
23. Kringen P., Bergamaschi A., Due E.U., Wang Y., Tagliabue E., Nesland J.M., et al. Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas. Biotechniques 39 (2005) 755-761
24. Newman L., Xia W., Yang H.Y., Sahin A., Bondy M., Lukmanji F., et al. Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcinog 30 (2001) 169-175
25. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., Chau V., et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269 (1995) 682-685